Search Results - "Johnson, Lisa D S"

Targeting CD47-SIRPa axis shows potent preclinical anti-tumor activity as monotherapy and synergizes with PARP inhibition by Al-Sudani, Hussein, Ni, Ying, Jones, Philip, Karakilic, Huseyin, Cui, Lei, Johnson, Lisa D. S., Rose, Peter G., Olawaiye, Alexander, Edwards, Robert P., Uger, Robert A., Lin, Gloria H. Y., Mahdi, Haider

“…The objective was to correlate CD47 gene expression with resistance to immune checkpoint inhibitors (ICI) in tumor tissue of gynecological cancer (GC)…”
Get full text

Polyfunctional T-cell responses are disrupted by the ovarian cancer ascites environment and only partially restored by clinically relevant cytokines by Tran, Eric, Nielsen, Julie S, Wick, Darin A, Ng, Alvin V, Johnson, Lisa D S, Nesslinger, Nancy J, McMurtrie, Elissa, Webb, John R, Nelson, Brad H

“…Host T-cell responses are associated with favorable outcomes in epithelial ovarian cancer (EOC), but it remains unclear how best to promote these responses in…”
Get full text

Transfusion management in the era of magrolimab (Hu5F9‐G4), an anti‐CD47 monoclonal antibody therapy by Singh, Nirupama, Staves, Julie, Storry, Jill R., Dinoso, Jason, Renard, Camille, Doshi, Parul, Johnson, Lisa D.S., Westhoff, Connie M., Murphy, Michael F.

Get full text

TGF-β sensitivity restrains CD8+ T cell homeostatic proliferation by enforcing sensitivity to IL-7 and IL-15 by Johnson, Lisa D S, Jameson, Stephen C

“…The pleiotropic cytokine TGF-β has been implicated in the regulation of numerous aspects of the immune response, including naïve T cell homeostasis. Previous…”
Get full text

Quantification of a proteotypic peptide from protein C inhibitor by liquid chromatography-free SISCAPA-MALDI mass spectrometry: application to identification of recurrence of prostate cancer by Razavi, Morteza, Johnson, Lisa D S, Lum, Julian J, Kruppa, Gary, Anderson, N Leigh, Pearson, Terry W

“…Biomarker validation remains one of the most challenging constraints to the development of new diagnostic assays. To facilitate biomarker validation, we…”
Get full text

A Chronic Need for IL-21 by Johnson, Lisa D. S., Jameson, Stephen C.

“…A cytokine produced by helper T cells enables CD8⁺ T cells to control viral infection…”
Get full text

Phase I Study of the CD47 Blocker TTI-621 in Patients with Relapsed or Refractory Hematologic Malignancies by Ansell, Stephen M, Maris, Michael B, Lesokhin, Alexander M, Chen, Robert W, Flinn, Ian W, Sawas, Ahmed, Minden, Mark D, Villa, Diego, Percival, Mary-Elizabeth M, Advani, Anjali S, Foran, James M, Horwitz, Steven M, Mei, Matthew G, Zain, Jasmine, Savage, Kerry J, Querfeld, Christiane, Akilov, Oleg E, Johnson, Lisa D S, Catalano, Tina, Petrova, Penka S, Uger, Robert A, Sievers, Eric L, Milea, Anca, Roberge, Kathleen, Shou, Yaping, O'Connor, Owen A

“…TTI-621 (SIRPα-IgG1 Fc) is a novel checkpoint inhibitor that activates antitumor activity by blocking the CD47 "don't eat me" signal. This first-in-human phase…”
Get full text

Negative regulators in homeostasis of naïve peripheral T cells by Modiano, Jaime F., Johnson, Lisa D. S., Bellgrau, Donald

“…It is now apparent that naïve peripheral T cells are a dynamic population where active processes prevent inappropriate activation while supporting survival…”
Get full text

The antigen-specific CD8+ T cell repertoire in unimmunized mice includes memory phenotype cells bearing markers of homeostatic expansion by Haluszczak, Catherine, Akue, Adovi D, Hamilton, Sara E, Johnson, Lisa D S, Pujanauski, Lindsey, Teodorovic, Lenka, Jameson, Stephen C, Kedl, Ross M

“…Memory T cells exhibit superior responses to pathogens and tumors compared with their naive counterparts. Memory is typically generated via an immune response…”
Get full text

The pivotal role of cytotoxic NK cells in mediating the therapeutic effect of anti-CD47 therapy in mycosis fungoides by Kruglov, Oleg, Johnson, Lisa D. S., Minic, Angela, Jordan, Kimberly, Uger, Robert A., Wong, Mark, Sievers, Eric L., Shou, Yaping, Akilov, Oleg E.

“…CD47 is frequently overexpressed on tumor cells and is an attractive therapeutic target. The mechanism by which anti-CD47 immunotherapy eliminates cutaneous…”
Get full text

Targeting CD47 in Sézary syndrome with SIRPαFc by Johnson, Lisa D.S., Banerjee, Swati, Kruglov, Oleg, Viller, Natasja Nielsen, Horwitz, Steven M., Lesokhin, Alexander, Zain, Jasmine, Querfeld, Christiane, Chen, Robert, Okada, Craig, Sawas, Ahmed, O'Connor, Owen A., Sievers, Eric L., Shou, Yaping, Uger, Robert A., Wong, Mark, Akilov, Oleg E.

“…Sézary syndrome (SS), the leukemic variant of cutaneous T-cell lymphoma, has limited treatment options and rare occurrences of long-term remission, thus…”
Get full text

Histidine rich glycoprotein and cancer: a multi-faceted relationship by Johnson, Lisa D S, Goubran, Hadi A, Kotb, Rami R

“…A better understanding of the interplay between the tumor environment, the immune system, and hemostatic apparatus is essential to effectively improve cancer…”
Get full text

Self-specific CD8+ T cells maintain a semi-naive state following lymphopenia-induced proliferation by Johnson, Lisa D S, Jameson, Stephen C

“…Upon transfer into T cell-deficient hosts, naive CD8(+) T cells typically undergo lymphopenia-induced proliferation (LIP, also called homeostatic…”
Get full text

TGF-[beta] Sensitivity Restrains CD8+ T Cell Homeostatic Proliferation by Enforcing Sensitivity to IL-7 and IL-15 by Johnson, Lisa D. S, Jameson, Stephen C

“…The pleiotropic cytokine TGF-[beta] has been implicated in the regulation of numerous aspects of the immune response, including naïve T cell homeostasis…”
Get full text

Abstract 2345: SIRPαFc, a CD47-blocking cancer immunotherapeutic, triggers phagocytosis of lymphoma cells by both classically (M1) and alternatively (M2) activated macrophages by Lin, Gloria H. Y., Chai, Vien, Lee, Vivian, Dodge, Karen, Truong, Tran, Wong, Mark, Johnson, Lisa D. S., Pang, Xinli, Petrova, Penka S., Uger, Robert A., Viller, Natasja N.

“…Abstract Macrophages are characterized by their heterogeneity and plasticity in response to the microenvironment. Although macrophages have the capacity to…”
Get full text

Intralesional Administration of the CD47 Antagonist TTI-621 (SIRPαFc) Induces Responses in Both Injected and Non-Injected Lesions in Patients with Relapsed/Refractory Mycosis Fungoides and Sézary Syndrome: Interim Results of a Multicenter Phase I Trial by Querfeld, Christiane, Thompson, John, Taylor, Matthew H., Pillai, Raju, Johnson, Lisa DS, Catalano, Tina, Petrova, Penka S., Thompson, Theresa, Uger, Robert A., Shou, Yaping, Akilov, Oleg E.

“…Background CD47 is an immune checkpoint that binds signal regulatory protein alpha (SIRPα) and delivers a “do not eat” signal to suppress macrophage…”
Get full text

Intralesional Injection of the CD47-blocking immune checkpoint inhibitor TTI-621 (SIRPaFc) induces antitumor activity in patients with relapsed/refractory mycosis fungoides and Sézary syndrome: Interim results of a multicenter Phase 1 trial by Querfeld, Christiane, Thompson, John A., Taylor, Matthew, Pillai, Raju, Johnson, Lisa DS, Catalano, Tina, Petrova, Penka S., Uger, Bob A., Irwin, Meghan, Thompson, Theresa, Sievers, Eric L., Akilov, Oleg

Get full text

A Single Direct Intratumoral Injection of TTI-621 (SIRPαFc) Induces Antitumor Activity in Patients with Relapsed/Refractory Mycosis Fungoides and Sézary Syndrome: Preliminary Findings Employing an Immune Checkpoint Inhibitor Blocking the CD47 “Do Not Eat” Signal by Querfeld, Christiane, Thompson, John, Taylor, Matthew, Pillai, Raju, Johnson, Lisa DS, Catalano, Tina, Petrova, Penka S., Uger, Robert A., Irwin, Meghan, Sievers, Eric L, Akilov, Oleg E.

“…Background CD47 is an immune checkpoint that binds to signal regulatory protein alpha (SIRPα) and delivers a “do not eat” signal to suppress macrophage…”
Get full text

Tumor-associated autoantibodies correlate with poor outcome in prostate cancer patients treated with androgen deprivation and external beam radiation therapy by Johnson, Lisa Ds, Nesslinger, Nancy J, Blood, Paul A, Chima, Navraj, Richier, Lindsay R, Ludgate, Charles, Pai, Howard H, Lim, Jan T, Nelson, Brad H, Vlachaki, Maria T, Lum, Julian J

“…Standard cancer treatments trigger immune responses that may influence tumor control. The nature of these responses varies depending on the tumor and the…”
Get full text

A Phase 1 Study of TTI-621, a Novel Immune Checkpoint Inhibitor Targeting CD47, in Patients with Relapsed or Refractory Hematologic Malignancies by Ansell, Stephen, Chen, Robert W, Flinn, Ian W., Maris, Michael B., O'Connor, Owen A., Johnson, Lisa DS, Irwin, Meghan, Petrova, Penka S., Uger, Robert A., Sievers, Eric L

“…Introduction The phagocytic activity of macrophages is regulated by activating ("eat") and inhibitory ("do not eat") signals. Under normal physiologic…”
Get full text